Rekvina Laboratories Limited has announced its audited standalone financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 21, 2026. The company reported a net loss of ₹25.47 lacs for the fiscal year, compared to a net loss of ₹13.71 lacs in the previous year. Revenue from operations for FY26 stood at ₹126.54 lacs, while total income for the period was ₹126.54 lacs.

Financial Performance

The company's financial performance for the year ended March 31, 2026, reflects the following key metrics:

For the quarter ended March 31, 2026, the company reported a net loss of ₹6.05 lacs on revenue from operations of ₹72.36 lacs. The total expenses for the quarter amounted to ₹78.41 lacs. The earnings per share (EPS) for the quarter was reported at (0.10).

Corporate Actions and Approvals

During the meeting, the Board approved several key corporate actions. The company approved the execution of a Share Exchange and Purchase Agreement for the acquisition of 100% equity share capital of Radiant Parenterals Limited for an aggregate consideration of ₹4,62,77,500. The consideration will be discharged by issuing 46,27,750 equity shares on a preferential basis. Additionally, the Board approved the issuance of 4,60,000 equity shares on a preferential basis to Amitkumar Arunkumar Rao and Amitkumar Arunkumar Rao HUF for cash consideration aggregating ₹46,00,000.

The Board also approved an increase in the Authorised Share Capital from ₹3,50,00,000 to ₹6,00,00,000. The company stated that these transactions are subject to shareholder and other regulatory approvals. The Board has not recommended any dividend for the financial year ended March 31, 2026.

Auditor's Report and Compliance

The statutory auditors, M/s. Y. M. Shah & Co., issued an unmodified opinion on the audited financial results. The report confirms that the results give a true and fair view of the company's financial position in conformity with Indian Accounting Standards. The declaration regarding the unmodified audit report was signed by Amit Mukesh Shah, Director of the company.

Rekvina Laboratories Limited has disclosed the official voting results for its Extra-Ordinary General Meeting (EGM) held on April 10, 2026, pursuant to Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting, conducted at the company's registered office in Vadodara, Gujarat, saw unanimous approval of all six proposed resolutions by shareholders.

Meeting Overview and Attendance

The EGM was successfully conducted on Friday, April 10, 2026, at 11:30 A.M. at 36, Sampatrao Colony, Next to Royal Hotel, Alkapuri, Vadodara, Gujarat. The meeting was chaired by Mr. Amit Mukesh Shah, Chairman & Managing Director, with comprehensive board representation and professional oversight.

Voting Results and Shareholder Participation

The voting process was conducted through remote e-voting facilitated by Central Depository Services Limited (CDSL), with the e-voting period commencing on April 6, 2026, at 9:00 A.M. and concluding on April 9, 2026, at 5:00 P.M. Mr. Suhas Bhattbhatt served as the appointed Scrutinizer to oversee the voting process and ensure transparency.

Key Resolutions Approved

All six critical resolutions were unanimously approved by the shareholders, focusing on capital enhancement and operational flexibility:

• Increase in Authorised Share Capital and alteration of Capital Clause of the Memorandum of Association
• Alteration of Articles of Association of the Company
• Investments, Loans, Guarantees and Security in excess of limits specified under Section 186 of Companies Act, 2013
• Approval of Related Party Transactions proposed to be entered into by the Company
• Issuance and Allotment of Equity Shares by way of preferential issue on private placement basis for consideration other than cash
• Issuance and Allotment of Equity Shares by way of preferential issue on private placement basis for cash consideration to non-promoter category

Regulatory Compliance and Documentation

The company has fulfilled its regulatory obligations by submitting the voting results along with the consolidated Scrutinizer's report to BSE Limited. The documentation includes comprehensive voting breakdowns across promoter and public categories, with detailed percentage calculations and compliance confirmations. The voting results and Scrutinizer's report have also been uploaded on the company's official website for transparency.

The unanimous approval of all resolutions demonstrates strong shareholder confidence in Rekvina Laboratories' strategic direction and capital restructuring initiatives, positioning the company for enhanced operational flexibility and growth opportunities.